13 July 2020 in Current Organic Chemistry
The viral infections are a threat to the health system around the globe. Although more than 60 antiviral drugs have been approved by the FDA, most of them are for the management of few viruses like HIV, Hepatitis and Influenza. There is no antiviral for many viruses including Dengue, Chikungunya and Japanese encephalitis. Many of these neglected viruses are increasingly becoming global pathogens. Lack of broad spectrum of action and the rapid rise of resistance and cross-resistance to existing antiviral have further increased the challenge of antiviral development. Sulfonamide, as a privileged scaffold, has been capitalized to develop several bioactive compounds and drugs. Accordingly, several reviews have been published in recent times on bioactive sulfonamides. However, there are not enough review reports of antiviral sulfonamides in the last five years. Sulfonamides scaffolds have received sufficient attention for the development of non- nucleoside antivirals following the emergence of cross-resistance to nucleoside inhibitors. Hybridization of bioactive pharmacophores with sulfonamides has been used as a strategy to develop sulfonamide antivirals. This review is an effort to analyze these attempts and evaluate their translational potential. Parameters including potency (IC50), toxicity (CC50) and selectivity (CC50/IC50) have been used in this report to suggest the potential of sulfonamide derivatives to progress further as antiviral. Since most of these antiviral properties are based on the in vitro results, the drug-likeness of molecules has been predicted to propose in vivo potential. The structure-activity relationship has been analyzed to encourage further optimization of antiviral properties.
21 December 2023 in ACS Omega
There is no approved antiviral for the management of the Chikungunya virus (CHIKV). To develop an antiviral drug that can manage both CHIKV and arthritis induced by it, an ester conjugate of telmisartan (TM) and salicylic acid (SA) was synthesized (DDABT1). It showed higher potency (IC50 of 14.53 mu M) and a good selectivity index [(SI = CC50/IC50) > 33]. On post-treatment of DDABT1, CHIKV infection was inhibited significantly by reducing CPE, viral titer, viral RNA, and viral proteins. Further, the time of addition experiment revealed >95% inhibition up to 4hpi indicating its interference predominantly in the early stages of infection. However, the late stages were also affected. This conjugate of SA and TM was found to increase the antiviral efficacy, and this might be partly attributed to modulating angiotensin II (Ang II) receptor type 1 (AT1). However, DDABT1 might have other modes of action that need further investigation. In addition, the in vivo experiments showed an LD50 of 5000 mg/kg in rats and was found to be more effective than TM, SA, or their combination against acute, subacute, and chronic inflammation/arthritis in vivo. In conclusion, DDABT1 showed remarkable anti-CHIKV properties and the ability to reduce inflammation and arthritis, making it a very good potential drug candidate that needs further experimental validation.
1 March 2025 in Current Computer-Aided Drug Design
Introduction: Arthritis is the cause of morbidity associated with Chikungunya virus (CHIKV) infection. It persists even after the virus has been cleared from the body. MBZM-NIBT was earlier shown to inhibit (CHIKV) infection in vitro and in vivo. Objective: The objective of this study is to determine the ability of MBZM-N-IBT to manage arthritis independent of CHIKV infection. Methods: The acute toxicity of MBZM-N-IBT was determined to find a permissible oral dose. Effects against inflammation and arthritis were determined in relevant preclinical models. Network pharmacology was used to propose possible modes of action. Results: It showed no acute toxicity orally, with an estimated LD50 of more than 5000 mg/kg in rats. It significantly reduced inflammation. Its effect against Complete Freund's Adjuvant (CFA) induced arthritis was comparable to that of Diclofenac sodium. Network pharmacology analysis revealed that MBZM-N-IBT can potentially interfere with multiple targets and pathways. MMP12 and CTSD were found to be the most probable hub targets of MBZM-N-IBT for its effect against arthritis. Conclusion: In conclusion, MBZM-N-IBT is safe at 50 mg/kg and can manage arthritis independent of CHIKV infection through modulation of multiple pathways and arthritis-associated targets.
25 June 2024 in Biomedical and Pharmacology Journal
Chikungunya virus (CHIKV) infection was previously found to be inhibited by MBZM-N-IBT both in vitro and in vivo. To further assess its suitability for in vivo application, toxicity and pharmacokinetics were investigated. It showed no acute toxicity orally with an estimated LD50 of more than 5000 mg/kg in rats. While it showed toxicity at 1000 mg/kg in the chronic toxicity study, it was better tolerated at 500 mg/kg by rats. At 50 mg/kg, it was found to be safe in a 9-month study. A pharmacokinetic study revealed Tmax less than the gastric emptying time. High plasma protein binding supported its higher elimination half-life. In silico analysis predicted 22 metabolites. The majority of these metabolites fall in OECD class 5 and support the low toxicity of MBZM-N-IBT.